Patents by Inventor Jean-Christophe Francis Audonnet
Jean-Christophe Francis Audonnet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10487334Abstract: The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formulations and/or compositions comprising a protein or an immunogen expressed using the drugless plasmids, and methods of administering such formulations and/or compositions to a host. The invention relates to gram negative bacteria containing the drugless plasmids.Type: GrantFiled: November 3, 2015Date of Patent: November 26, 2019Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Jean-Christophe Francis Audonnet, Edmond Jolivet
-
Publication number: 20160312231Abstract: The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formulations and/or compositions comprising a protein or an immunogen expressed using the drugless plasmids, and methods of administering such formulations and/or compositions to a host. The invention relates to gram negative bacteria containing the drugless plasmids.Type: ApplicationFiled: November 3, 2015Publication date: October 27, 2016Applicant: MERIAL INC.Inventors: Jean-Christophe Francis Audonnet, Edmond Jolivet
-
Patent number: 9217153Abstract: The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formulations and/or compositions comprising a protein or an immunogen expressed using the drugless plasmids, and methods of administering such formulations and/or compositions to a host. The invention relates to gram negative bacteria containing the drugless plasmids.Type: GrantFiled: May 24, 2010Date of Patent: December 22, 2015Assignee: MERIAL, INC.Inventors: Jean Christophe Francis Audonnet, Edmond Jolivet
-
Patent number: 8535682Abstract: An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: GrantFiled: April 12, 2010Date of Patent: September 17, 2013Assignee: Merial LimitedInventors: Sheena May Loosmore, Jean-Christophe Francis Audonnet, Jules Maarten Minke
-
Patent number: 8420389Abstract: The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.Type: GrantFiled: July 20, 2010Date of Patent: April 16, 2013Assignee: Merial LimitedInventor: Jean Christophe Francis Audonnet
-
Patent number: 7998733Abstract: The present invention relates to chimeric vectors. More specifically, the invention relates to recombinant poxvirus vectors and viruses that are capable of expressing an alphaviral RNA replicon expressing a heterologous sequence of interest.Type: GrantFiled: October 5, 2004Date of Patent: August 16, 2011Assignee: Merial LimitedInventors: Jiansheng Yao, Sheena May Loosmore, Jean-Christophe Francis Audonnet
-
Patent number: 7862821Abstract: The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against Orbiviruses, more specifically bluetongue virus (BTV) in an animal susceptible to BTV infection. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain heterologous nucleic acid molecule(s), expresses in vivo in the animal BTV antigen, immunogen or epitope thereof, e.g., BTV VP2; BTV VP2 and VP5; BTV VP2 and VP5 and VP3 and/or VP7. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: GrantFiled: June 1, 2006Date of Patent: January 4, 2011Assignees: Merial Limited, The Regents of the University of CaliforniaInventors: Jean Christophe Francis Audonnet, Kemal Karaca, Jiansheng Yao, Nigel James MacLachlan
-
Publication number: 20100298419Abstract: The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formulations and/or compositions comprising a protein or an immunogen expressed using the drugless plasmids, and methods of administering such formulations and/or compositions to a host. The invention relates to gram negative bacteria containing the drugless plasmids.Type: ApplicationFiled: May 24, 2010Publication date: November 25, 2010Inventors: Jean Christophe Francis Audonnet, Edmond Jolivet
-
Publication number: 20100278862Abstract: The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.Type: ApplicationFiled: July 20, 2010Publication date: November 4, 2010Inventor: Jean-Christophe Francis Audonnet
-
Patent number: 7803612Abstract: The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.Type: GrantFiled: April 14, 2006Date of Patent: September 28, 2010Assignee: Merial LimitedInventor: Jean Christophe Francis Audonnet
-
Publication number: 20100221282Abstract: An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: ApplicationFiled: April 12, 2010Publication date: September 2, 2010Inventors: SHEENA MAY LOOSMORE, JEAN-CHRISTOPHE FRANCIS AUDONNET, JULES MAARTEN MINKE
-
Patent number: 7740863Abstract: An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: GrantFiled: November 17, 2003Date of Patent: June 22, 2010Assignee: MerialInventors: Sheena May Loosmore, Jean-Christophe Francis Audonnet, Jules Maarten Minke
-
Publication number: 20090253185Abstract: The present invention relates to modified poxyiral vectors and to methods of making and using the same. In particular, the invention relates to recombinant avipox that expresses gene products of foot and mouth disease virus (FMDV), and to compositions or vaccines that elicit immune responses directed to FMDV gene products and which can confer protective immunity against infection by FMDV.Type: ApplicationFiled: May 4, 2009Publication date: October 8, 2009Inventors: Robert Nordgren, Sheena May Loosmore, Jean-Christophe Francis Audonnet, Marvin J. Grubman
-
Patent number: 7531182Abstract: A vaccine against foot-and-mouth disease, using as antigen an efficient amount of empty capsids of the foot-and-mouth virus. The empty capsids are obtained by expressing, in eukaryotic cells, cDNA of the P1 region of the foot-and-mouth virus genome coding for the capsid and cDNA of the region of the foot-and-mouth virus genome coding for protease 3C. The vaccine further includes a carrier or excipient pharmaceutically acceptable in veterinary medicine.Type: GrantFiled: December 20, 2002Date of Patent: May 12, 2009Assignee: Merial LimitedInventors: Andrew Maurice Quatermain King, Alison Jane Burman, Jean-Christophe Francis Audonnet, Michel Francois Antoine Lombard
-
Patent number: 7527960Abstract: The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant avipox that expresses gene products of foot and mouth disease virus (FMDV), and to compositions or vaccines that elicit immune responses directed to FMDV gene products and which can confer protective immunity against infection by FMDV.Type: GrantFiled: April 20, 2005Date of Patent: May 5, 2009Assignee: Merial LimitedInventors: Robert Nordgren, Sheena May Loosmore, Jean-Christophe Francis Audonnet, Marvin J. Grubman
-
Patent number: 7507416Abstract: The recombinant live vaccine comprises a viral vector incorporating and expressing in vivo a heterologous nucleotide sequence, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative. It is in particular a polymer of acrylic or methacrylic acid cross-linked with a polyalkenyl ether of a sugar or polyalcohol (carbomer), in particular cross-linked with an allyl sucrose or with allylpentaerythritol. It may also be a copolymer of maleic anhydride and ethylene cross-linked, for example, with divinyl ether.Type: GrantFiled: December 12, 2003Date of Patent: March 24, 2009Assignee: Merial LimitedInventors: Jean-Christophe Francis Audonnet, Jules Maarten Minke
-
Patent number: 7455844Abstract: The invention relates to subunit immunogenic or vaccine compositions which may comprise at least one polypeptide of Streptococcus equi and methods for preparing and/or formulating such compositions. The invention also relates to the use of such subunit compositions, such as a method for eliciting an immunogenic response or a protective immune response, which may comprise administering the composition to a mammal susceptible to streptococcal infection.Type: GrantFiled: March 29, 2007Date of Patent: November 25, 2008Assignee: Merial LimitedInventors: Jules Maarten Minke, Jean-Christophe Francis Audonnet
-
Publication number: 20080274137Abstract: The present invention relates to compositions and methods to improve expression of exogenous polypeptides, such as an antigen, epitope, immunogen, peptide or polypeptide of interest. More particularly, the present invention provides for DNA plasmids with increased expression and stability in compositions and methods useful for DNA vaccines.Type: ApplicationFiled: May 2, 2007Publication date: November 6, 2008Inventor: Jean Christophe Francis Audonnet
-
Publication number: 20070280960Abstract: The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against Orbiviruses, more specifically bluetongue virus (BTV) in an animal susceptible to BTV infection. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain heterologous nucleic acid molecule(s), expresses in vivo in the animal BTV antigen, immunogen or epitope thereof, e.g., BTV VP2; BTV VP2 and VP5; BTV VP2 and VP5 and VP3 and/or VP7. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: ApplicationFiled: June 1, 2006Publication date: December 6, 2007Inventors: Jean Christophe Francis Audonnet, Kemal Karaca, Jiansheng Yao, Nigel James MacLachlan
-
Patent number: 7211379Abstract: Provided is a method for reducing viral load of porcine circovirus type 2 (PCV-2) in a pig by inducing an immune response against PCV-2 through the administration of an immunogenic composition comprising a PCV-2 antigen. A preferred antigen is a vector containing a PCV-2 nucleotide sequence. In a particularly preferred embodiment, the PCV-2 nucleotide sequence is ORF4, ORF13, or ORF4 and ORF13. In some embodiments, the immunogenic composition includes one or more additional pig pathogens.Type: GrantFiled: February 17, 2004Date of Patent: May 1, 2007Assignee: Merial SASInventors: John Ellis, Gordon Moore Allan, Brian Meehan, Edward Clark, Deborah Haines, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, George Steve Krakowka, Jean-Christophe Francis Audonnet, Francis McNeilly